Navigation Links
ThromboGenics Announces Half Year Results 2008
Date:8/28/2008

lasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development by the end of 2008, and TB-403 (Anti-PlGF). ThromboGenics and its development partner BioInvent, have recently signed a license agreement with Roche for TB-403 worth up to EUR500 million plus royalties. A Phase Ib clinical trial with TB-403 has recently begun in patients with late stage cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

For further information please contact:

Thro
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
2. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
3. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
4. ThromboGenics N.V. - Business Update
5. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
6. ThromboGenics Announces 2007 Full Year Results
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
9. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
10. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
11. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Ontotext S4 , The ... Ontotext . Now the same enterprise hardened text ... and unstructured data is available to start-ups and mid-size ... technology. Organizations that do not have resources to evaluate ... use S4 since there is no need for on ...
(Date:8/20/2014)... Clintrax Global, Inc., a worldwide provider ... Raleigh, NC , recently announced the addition ... of Administration. As Vice President ... including their alignment with company objectives and policies.  ... an HR executive, specializing in needs assessments, customer ...
(Date:8/20/2014)... Aug. 20, 2014 Neurotrope, Inc. (OTCQB: ... conference call to provide an update on Company ... daylight timeDial-in numbers:(888) 505-4369 (U.S. and Canada) or ... cast: www.neurotropebioscience.com , under "Investor Relations"The teleconference replay ... through September 2, 2014 at (888) 203-1112 (U.S. ...
(Date:8/20/2014)... San Francisco, CA (PRWEB) August 20, 2014 ... Medicine Conference is being held on October 29-30 ... fresh perspectives from industry, academic and government researchers and ... remaining in the space. , In the twelve ... than one hundred therapies have been introduced with pharmacogenetic ...
Breaking Biology Technology:Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Clintrax Global, Inc. Announces Addition to Executive Team 2Neurotrope To Host Conference Call 26th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2
... Medical Systems, Inc.,today announced it has signed a ... developer of premium ultrasound systems, for the distribution ... care market in North,America and select countries internationally. ... ultrasound, PACS (Picture Archiving and,Communications Systems) and Practice ...
... Dec. 10 VIASPACE Inc. (OTC Bulletin Board: VSPC) ... proprietary fast-growing China Giant King Grass near the IPA factory in ... hybrid perennial grass which is propagated from seedlings rather than seeds. ... can yield four crops per year and up to 156 tons ...
... and NEEDHAM, Massachusetts, December 10 /PRNewswire-FirstCall/,-- Oridion ... announced that,three substantial medical research project findings ... Association for Respiratory Care) Congress in,Anaheim, California. ... End-tidal,CO2 (EtCO2) monitoring using Oridion Microstream(R) capnography ...
Cached Biology Technology:Eklin Signs Letter of Intent With ZONARE for Distribution of Zone Sonography(TM) z.one System 2Eklin Signs Letter of Intent With ZONARE for Distribution of Zone Sonography(TM) z.one System 3VIASPACE Plants Biofuel & Animal Feed Grass and Signs Land Lease in China 2VIASPACE Plants Biofuel & Animal Feed Grass and Signs Land Lease in China 3Oridion Announces Significant Medical Research to be Presented at AARC Congress 2Oridion Announces Significant Medical Research to be Presented at AARC Congress 3
(Date:8/21/2014)... researchers at Louisiana Tech University has developed ... 3D printers and materials to fabricate custom ... chemotherapeutic compounds for targeted drug delivery. , ... research faculty from Louisiana Tech,s biomedical engineering ... filament extruders that can make medical-quality 3D ...
(Date:8/20/2014)... of 158 pregnant teenagers in Rochester, NY, nearly half ... of ice, cornstarch, vacuum dust, baby powder and soap, ... , Moreover, such teens had significantly lower iron levels ... substances. , Pregnant teens, regardless of pica, are at ... iron deficiency and anemia. Low iron in pregnant teens ...
(Date:8/20/2014)... image of the Para and Mato Grosso states of ... set in order to deforest the land. Deforestation is ... where the land is thereafter converted to a nonforest ... farms, ranches, or urban use. The herringbone-patterned tan lines ... in the middle of the image are evidence of ...
Breaking Biology News(10 mins):Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Pica in pregnant teens linked to low iron 2
... Energy,s Pacific Northwest National Laboratory will present a variety ... Union Fall Meeting, which runs Monday, Dec. 3 through ... San Francisco. Topics to be discussed include improving solar ... for biofuel and predicting the environmental impacts of ocean ...
... PhD, the Louis Block Distinguished Service Professor of Medicine ... Diabetes Center at the University of Chicago, has been ... his pioneering work in understanding the role of genetics ... The prize, the world,s largest award for diabetes research, ...
... NY, December 4, 2012Human mesenchymal stem cells (hMSCs) can ... engineering and regeneration. However, when grown in the laboratory ... they die. A method for genetically engineering hMSCs so ... become bone cells is described in an article published ...
Cached Biology News:Sunshine, biofuel and the tides, oh my! 2Sunshine, biofuel and the tides, oh my! 3University of Chicago's Graeme Bell receives international diabetes prize 2University of Chicago's Graeme Bell receives international diabetes prize 3
... anti-Cytohesin 2, Monoclonal Antibody, Unconjugated ... dependent dilution. ICC: Use at an assay dependent ... - 10 ug/ml, this concentration is determined using ... weight: 40 kDa. Not tested in other applications. ...
Recognizes TWIK-2. Does not cross react with any other known proteins....
Anti human PPAR gamma2 mouse monoclonal antibody...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
Biology Products: